Figure 3
From: A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Time to progression (a) and overall survival (b) in 77 eligible patients with relapsed aggressive NHL treated with single-agent everolimus.
Figure 3 | Leukemia
